Chankit Giri
Research Scholar
CSIR–Institute of Microbial Technology (CSIR-IMTECH), Chandigarh, India
This article is an independent literature synthesis prepared strictly to communicate recent advances in ribosomal target identification, support student learning, and promote educational awareness.
Legal & Academic DisclaimerAntimicrobial resistance (AMR) has emerged as one of the most serious threats to global health. According to the World Health Organization, bacterial pathogens are evolving resistance faster than new antibiotics are entering clinical practice. Routine surgeries, cancer chemotherapy, neonatal care, organ transplantation and intensive care medicine all depend upon antibiotics that remain effective. Unfortunately, the antibiotic discovery pipeline has slowed considerably over the last three decades.
Against this backdrop, researchers continue searching for completely new molecules that attack bacteria in different ways. Instead of modifying existing antibiotics, scientists are increasingly exploring natural products hidden within microorganisms. One such discovery is manikomycin, a natural antibiotic recently described in a landmark publication in Nature (2026).
Although manikomycin is still years away from becoming a medicine, its discovery has attracted worldwide attention because it interacts with bacteria through a previously unexplored mechanism. This finding demonstrates that nature continues to surprise scientists, even within microorganisms that have been investigated for decades.
The research was carried out by an international team of microbiologists, structural biologists and medicinal chemists. Among the leading contributors is Dr. Nora Vázquez Laslop from the University of Illinois Chicago (UIC). Working together with collaborators across multiple research institutions, the team identified, isolated and characterized a previously unknown natural antibiotic from the soil bacterium Streptomyces rimosus.
Their work combined modern microbiology, high-resolution structural biology, chemical analysis, and ribosome biology to understand not only what this molecule is, but also how it inhibits bacterial growth. The study was subsequently published in Nature, one of the world's leading scientific journals.
Manikomycin is a newly characterized natural depsipeptide antibiotic produced by Streptomyces rimosus, a soil-dwelling bacterium already famous for producing oxytetracycline.
Interestingly, Streptomyces rimosus has been studied by microbiologists for more than seventy years. Scientists believed that nearly all of its antibiotic-producing capabilities had already been discovered. However, using advanced analytical techniques, the research team identified a previously hidden metabolite that had escaped detection because it is naturally produced in extremely small amounts.
This discovery serves as an important reminder that even microorganisms investigated for decades may still contain chemically unique molecules capable of inspiring future medicines.
Many antibiotics used in modern medicine target the bacterial ribosome, the molecular machine responsible for synthesizing proteins. Drugs such as tetracyclines, macrolides, aminoglycosides, oxazolidinones, and chloramphenicol inhibit protein synthesis by binding to well-characterized regions of the ribosome.
The challenge is that bacteria have spent decades evolving resistance against these antibiotic classes. Mutations in ribosomal RNA, enzymatic modification of antibiotics, active efflux pumps, and reduced membrane permeability have collectively reduced the effectiveness of many clinically important drugs.
Manikomycin offers something different.
Using high-resolution cryo-electron microscopy, the researchers demonstrated that manikomycin binds to the E-site (Exit site) of the bacterial large ribosomal subunit. According to the authors, this region has not previously been exploited by approved antibiotics.
Instead of competing with existing ribosome-targeting antibiotics, manikomycin interacts with a distinct structural pocket, providing researchers with an entirely new framework for designing future antibacterial compounds.
During bacterial protein synthesis, transfer RNA (tRNA) molecules move sequentially through three ribosomal binding sites:
The Nature study demonstrates that manikomycin binds near the E-site and interferes with normal ribosomal function. As a result, bacterial protein synthesis is disrupted, preventing continued bacterial growth.
Although manikomycin is still a research molecule rather than an approved medicine, its discovery is scientifically significant for several reasons.
Importantly, the discovery should not be interpreted as meaning bacteria cannot develop resistance against manikomycin in the future. Instead, it provides researchers with a valuable starting point for developing antibiotics that operate differently from existing drugs.
Antimicrobial resistance continues to increase worldwide because bacteria constantly evolve under selective pressure created by antibiotic exposure.
Many multidrug-resistant pathogens—including Acinetobacter baumannii, Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant enterococci—have acquired multiple mechanisms that reduce antibiotic susceptibility.
One long-term strategy for overcoming resistance is to identify completely new bacterial targets rather than repeatedly modifying existing antibiotics.
In this context, manikomycin represents more than just another antibiotic candidate; it illustrates how modern microbiology, structural biology, and natural-product chemistry can uncover previously hidden opportunities for drug discovery.
No.
The discovery reported in Nature represents an important scientific advance, but manikomycin is not yet approved for clinical use.
The researchers note that further work is required to improve its stability, pharmacological properties, toxicity profile, and overall suitability for therapeutic development.
Like many newly discovered natural products, it should currently be regarded as a lead compound rather than a finished drug.
Perhaps the most inspiring aspect of this study is the broader lesson it teaches.
Scientists often assume that microorganisms investigated for decades have already revealed all of their secrets. The discovery of manikomycin challenges that assumption and highlights the remarkable chemical diversity that still exists within nature.
With advances in genome mining, metabolomics, cryo-electron microscopy, artificial intelligence, and synthetic biology, researchers are now better equipped than ever to uncover hidden antibiotics that were previously impossible to detect.
As antimicrobial resistance continues to threaten global healthcare, discoveries like manikomycin provide renewed optimism that innovative science can still reveal powerful solutions from the microbial world.
The discovery of manikomycin is an excellent example of curiosity-driven science leading to meaningful advances in antibiotic research.
Although much work remains before this molecule could become a therapeutic agent, identifying a previously untargeted ribosomal binding site significantly expands our understanding of bacterial biology and antibiotic mechanisms.
Every new antibacterial target strengthens the fight against antimicrobial resistance. Whether manikomycin itself reaches the clinic or simply inspires the next generation of antibiotics, its discovery represents an important milestone in modern microbiology.
Chankit Giri
Research Scholar
CSIR–Institute of Microbial Technology (CSIR-IMTECH), Chandigarh, India
This article is an independent scientific summary prepared to communicate recent advances in antimicrobial resistance and antibiotic discovery. It is intended for students, researchers, educators, and anyone interested in microbiology and infectious diseases.